EFFECT OF THYMIDINE ON THE SURVIVAL OF MICE WITH EL4 TUMORSREITER H.1979; CANCER RES.; USA; DA. 1979; VOL. 39; NO 12; PP. 4856-4860; BIBL. 10 REF.Article

THYMIDINE ENHANCEMENT OF 1-BETA -D-ARABINOFURANOSYLCYTOSINE ACTIVITY FOR MOUSE EL4 TUMORSREITER H.1981; LEUK. RES.; ISSN 0145-2126; USA; DA. 1981; VOL. 5; NO 3; PP. 259-263; BIBL. 12 REF.Article

RABBIT ANTI-EL 4 SERUM: A REAGENT WITH SPECIFICITY FOR A POPULATION OF MURINE SUPPRESSOR CELLSAL SAKKAF L; COOKE A; HUTCHINGS P et al.1979; IMMUNOLOGY; GBR; DA. 1979; VOL. 38; NO 2; PP. 375-383; BIBL. 24 REF.Article

IN VIVO SUPPRESSION OF EL4 LYMPHOMA BY RABBIT ANTITUMOR SERA.GHOSE T; GUCLU A; FAULKNER J et al.1977; J. NATION. CANCER INST.; U.S.A.; DA. 1977; VOL. 58; NO 3; PP. 693-700; BIBL. 21 REF.Article

Atypical mannolipids characterize Thy-1-negative lymphoma mutantsLEMANSKY, P; GUPTA, D. K; MEYALE, S et al.Molecular and cellular biology (Print). 1991, Vol 11, Num 8, pp 3879-3885, issn 0270-7306Article

ANTITUMOR PROPERTIES OF CHEMICALLY DETOXIFIED KILLED BRUCELLA ABOCTUS ORGANISMSLEGARREC Y; MARTIN A; COLLET B et al.1981; CANCER IMMUNOL. IMMUNOTHER.; ISSN 0340-7004; DEU; DA. 1981; VOL. 11; NO 1; PP. 63-68; BIBL. 23 REF.Article

SUPPRESSION AND RESTORATION OF CYTOTOXIC T-CELL ACTIVITY DURING CHEMOTHERAPY OF A MOUSE T-CELL LYMPHOMA AND A MACROPHAGE TUMORTARNOWSKI GS; FAANES RB; RALPH P et al.1978; CANCER RES.; USA; DA. 1978; VOL. 38; NO 12; PP. 4540-4545; BIBL. 24 REF.Article

COVALENT BINDING OF METHOTREXATE TO IMMUNOGLOBULINS AND THE EFFECT OF ANTIBODY-LINKED DRUG ON TUMOR GROWTH IN VIVOKULKARNI PN; BLAIR AH; GHOSE TI et al.1981; CANCER RES.; ISSN 0008-5472; USA; DA. 1981; VOL. 41; NO 7; PP. 2700-2706; BIBL. 33 REF.Article

HYBRID RESISTANCE TO EL-4 LYMPHOMA CELLS. I. CHARACTERIZATION OF NATURAL KILLER CELLS THAT LYSE EL-4 CELLS AND THEIR DISTINCTION FROM MARROW-DEPENDENT NATURAL KILLER CELLSVINAY KUMAR; LUEVANO E; BENNETT M et al.1979; J. EXPER. MED.; USA; DA. 1979; VOL. 150; NO 3; PP. 531-547; BIBL. 33 REF.Article

THE SPONTANEOUS RELEASE OF ⁵¹CR FROM LABELED EL-4 ASCITIC LYMPHOMA CELLS AS DEPENDENT UPON THE COMPOSITION OF THE CELL POPULATION.DEBERNARDO E; CLAUS G; KRISKO I et al.1977; EXPER. CELL. BIOL.; SWITZ.; DA. 1977; VOL. 45; NO 3-4; PP. 122-140; BIBL. 3 P.Article

INFLUENCE OF C. PARVUM ON THE EFFECTIVENESS OF PASSIVE SEROTHERAPY IN THE CONTROL OF THE EL4 LYMPHOMA IN C57BL/6 MICEO'NEILL GJ; STEBBING N.1980; BRIT. J. CANCER; GBR; DA. 1980; VOL. 41; NO 2; PP. 243-249; BIBL. 19 REF.Article

SENSITIVITY TO CHEMOTHERAPEUTIC AND IMMUNOMODULATING AGENTS OF TWO MOUSE LYMPHOMAS AND OF A MACROPHAGE TUMORTARNOWSKI GS; RALPH P; STOCK CC et al.1979; CANCER RES.; USA; DA. 1979; VOL. 39; NO 10; PP. 3964-3967; BIBL. 8 REF.Article

TARGET-EFFECTOR INTERACTION IN THE NATURAL KILLER CELL SYSTEM: ISOLATION OF TARGET STRUCTURESRODER JC; ROSEN A; FENYO EM et al.1979; PROC. NATION. ACAD. SCI. U.S.A.; USA; DA. 1979; VOL. 76; NO 3; PP. 1405-1409; BIBL. 13 REF.Article

AUGMENTATION DE LA RESISTANCE CONTRE LA GREFFE TUMORALE CHEZ DES ANIMAUX INFECTES PAR DES SOUCHES VACCINALES DE BRUCELLA ABORTUSDAZORD L; LE GARREC Y; BONNIER M et al.1979; ; FRA; DA. 1979; DGRST-76 7 1687; (11)-9 P.-PL.; 30 CM; BIBL. DISSEM.; ACTION CONCERTEE: CANCEROGENESE ET PHARMACOLOGIE DU CANCERReport

⁵⁷CO-BLEOMYCIN KINETICS IN NORMAL AND TUMOUR-BEARING MICE AFTER SYSTEMATIC AND LOCAL ADMINISTRATIONBIER J; BENDERS P; BITTER K et al.1979; J. MAXILLOFACIAL SURG.; DEU; DA. 1979; VOL. 7; NO 1; PP. 32-40; BIBL. 14 REF.Article

Insulin-tumour interrelationship in EL4 lymphoma or thymoma-bearing mice. I, Alloxan-diabetic or non-diabetic miceYAM, D; ZILBERSTEIN, A; FINK, A et al.British journal of cancer. 1990, Vol 61, Num 5, pp 689-694, issn 0007-0920Article

Immunogenic potential of tumor cells after treatment with antitumor chemotherapeutic agentsUJIIE, T.Japanese journal of experimental medicine. 1988, Vol 58, Num 1, pp 33-38, issn 0021-5031Article

Increased mitochondrial uptake of rhodamine 123 by CDDP treatmentSHINOMIYA, N; TSURU, S; KATSURA, Y et al.Experimental cell research. 1992, Vol 198, Num 1, pp 159-163, issn 0014-4827Article

Cell surface antigen CD5 is a marker for activated human B cellsWERNER-FAVRE, C; VISCHER, T. L; WOHLWEND, D et al.European journal of immunology. 1989, Vol 19, Num 7, pp 1209-1213, issn 0014-2980Article

Characterization of plasma membrane domains of mouse EL₄ lymphoma cells obtained by affinity chromatography on concanavalin A-sepharoseSZAMEL, M; GOPPELT, M; RESCH, K et al.Biochimica et biophysica acta. 1985, Vol 821, Num 3, pp 479-487, issn 0006-3002Article

Tumor and tissue distribution of a methotrexate-anti-EL4 immunoglobulin conjugate in EL4 lymphoma-bearing miceUADIA, P; BLAIR, A. H; TARUNENDU GHOSE et al.Cancer research (Baltimore). 1984, Vol 44, Num 10, pp 4263-4266, issn 0008-5472Article

Plasticity of T cell function: cloned EL-4 lymphoma cells may help or suppress a primary antibody response depending on their own concentration and the assay systemMELCHERS, I; RZEPKA, R.The Journal of immunology (1950). 1988, Vol 141, Num 9, pp 2873-2881, issn 0022-1767Article

The interleukin-1 receptor in Raji human B-lymphoma cells: molecular characterization and evidence for receptor-mediated activation of gene expressionHORUK, RT; MCCUBREY, J. A.Biochemical journal (London. 1906). 1989, Vol 260, Num 3, pp 657-663, issn 0006-2936Article

Augmentation of antitumor effect by combined administration with interleukin-2 and sizofiran, a single glucan, on murine EL-4 lymphomaKANO, Y; KAKUTA, H; HASHIMOTO, J et al.Biotherapy (Dordrecht). 1996, Vol 9, Num 4, pp 241-247, issn 0921-299XArticle

Regulation of interleukin 2 gene expression: discrepancy between enhancer activity and endogenous gene expressionMARTENSSON, I.-L; LEANDERSON, T.European journal of immunology. 1989, Vol 19, Num 1, pp 145-149, issn 0014-2980Article